NPPA rationalises trade margins for 137 non-scheduled anti-cancer drugs
Quick dive
- NPPA has undertaken trade-margin rationalisation for 137 identified non-scheduled anti-cancer drugs to improve affordability and access.
- The government expects maximum retail prices of the identified drugs to fall by up to 70%, depending on existing price structures.
- Trade margins are capped at 30% of MRP under the Drugs (Prices Control) Order, 2013, for the affected medicines.
- The revised prices are scheduled to become effective on November 9, according to the report.
- exam_relevance: tests the difference between scheduled and non-scheduled medicines, trade-margin regulation under DPCO 2013 and the public-health objective of price intervention in cancer care.
Full explanation
This explanation is available with full current-affairs access.
Log in to continue